Literature DB >> 26706283

Norrin mediates angiogenic properties via the induction of insulin-like growth factor-1.

Ludwig F Zeilbeck1, Birgit B Müller1, Stephanie A Leopold1, Berna Senturk1, Thomas Langmann2, Ernst R Tamm1, Andreas Ohlmann3.   

Abstract

Norrin is an angiogenic signaling molecule that activates canonical Wnt/β-catenin signaling, and is involved in capillary formation in retina and brain. Moreover, Norrin induces vascular repair following an oxygen-induced retinopathy (OIR), the model of retinopathy of prematurity in mice. Since insulin-like growth factor (IGF)-1 is a very potent angiogenic molecule, we investigated if IGF-1 is a downstream mediator of Norrin's angiogenic properties. In retinae of transgenic mice with an ocular overexpression of Norrin (βB1-Norrin), we found at postnatal day (P)11 a significant increase of IGF-1 mRNA compared to wild-type littermates. In addition, after treatment of cultured Müller cells or dermal microvascular endothelial cells with Norrin we observed an increase of IGF-1 and its mRNA, an effect that could be blocked with DKK-1, an inhibitor of Wnt/β-catenin signaling. When OIR was induced, the expression of IGF-1 was significantly suppressed in both transgenic βB1-Norrin mice and wild-type littermates when compared to wild-type animals that were housed in room air. Furthermore, at P13, one day after the mice had returned to normoxic conditions, IGF-1 levels were significantly higher in transgenic mice compared to wild-type littermates. Finally, after intravitreal injections of inhibitory α-IGF-1 antibodies at P12 or at P12 and P14, the Norrin-mediated vascular repair was significantly attenuated. We conclude that Norrin induces the expression of IGF-1 via an activation of the Wnt/β-catenin signaling pathway, an effect that significantly contributes to the protective effects of Norrin against an OIR.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; IGF-1; Norrin; Oxygen-induced retinopathy; Retinopathy of prematurity; Wnt signaling; β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26706283     DOI: 10.1016/j.exer.2015.12.001

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  7 in total

Review 1.  Wnt Signaling in vascular eye diseases.

Authors:  Zhongxiao Wang; Chi-Hsiu Liu; Shuo Huang; Jing Chen
Journal:  Prog Retin Eye Res       Date:  2018-12-01       Impact factor: 21.198

2.  Oxidative stress upregulates Wnt signaling in human retinal microvascular endothelial cells through activation of disheveled.

Authors:  Chi Zhang; Elizabeth Tannous; Jie J Zheng
Journal:  J Cell Biochem       Date:  2019-04-08       Impact factor: 4.429

3.  Norrin mediates opposing effects on tumor progression of glioblastoma stem cells.

Authors:  Stefan Kassumeh; Siegfried G Priglinger; Andreas Ohlmann
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

4.  Norrin restores blood-retinal barrier properties after vascular endothelial growth factor-induced permeability.

Authors:  Mónica Díaz-Coránguez; Cheng-Mao Lin; Stefan Liebner; David A Antonetti
Journal:  J Biol Chem       Date:  2020-02-21       Impact factor: 5.157

Review 5.  Current understanding of the molecular and cellular pathology of diabetic retinopathy.

Authors:  David A Antonetti; Paolo S Silva; Alan W Stitt
Journal:  Nat Rev Endocrinol       Date:  2021-01-19       Impact factor: 47.564

6.  Blood protein profiles related to preterm birth and retinopathy of prematurity.

Authors:  Hanna Danielsson; Abdellah Tebani; Wen Zhong; Linn Fagerberg; Nele Brusselaers; Anna-Lena Hård; Mathias Uhlén; Ann Hellström
Journal:  Pediatr Res       Date:  2021-04-24       Impact factor: 3.953

7.  Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma.

Authors:  Stephanie A Leopold; Ludwig F Zeilbeck; Gregor Weber; Roswitha Seitz; Michael R Bösl; Herbert Jägle; Rudolf Fuchshofer; Ernst R Tamm; Andreas Ohlmann
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.